The immunohistochemical expression of p53 and Ki67 in ovarian epithelialborderline tumors. Correlation with clinicopathological factors

Romanian Journal of Morphology and Embryology

Volumn 53, Issue 4, 2012, Pages 967-973

  Giurgea, Luminiţa Nicoleta ^a,b   Ungureanu, Carmen ^b   Mihailovici, Maria Sultana ^b  

^a 'Mavromati' Emergency County Hospital   (Romania)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Borderline tumor; Ki67; Ovarian tumor; P53

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872258631     PISSN: 12200522     EISSN: 20668279     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Longacre TA, Gilks CB, Surface epithelial stromal tumors of ovary. In: Nucci MR, Oliva E (eds), Gynecologic pathology, Elsevier Churchill Livingstone, 2009, 390-450.
2. Raspollini LM, Taddei GL, Tumor markers in ovarian carcinoma, Int J Gynaecol Obstet, 2007, 97(3):175-181.
3. Le Page C, Huntsman DG, Provencher DM, Mes-Masson AM, Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies, Cancers, 2010, 2(2):913-954.
4. Kmet LM, Cook LS, Magliocco AM, A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors, Cancer, 2003, 97(2):389-404.
5. Khouja MH, Baekelandt M, Nesland JM, Holm R, The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma, Int J Gynecol Pathol, 2007, 26(4):418-425.
6. Seidman JD, Kurman RJ, Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators, Hum Pathol, 2000, 31(5):539-557.
7. Kurman RJ, Seidman JD, Shih IM, Serous borderline tumours of the ovary, Histopathology, 2005, 47(3):310-315.
8. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR, Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up, Am J Surg Pathol, 2005, 29(6):707-723.
9. Kurman RJ, Shih IeM, Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications, Int J Gynecol Pathol, 2008, 27(2):151-160.
10. Sherman ME, Berman J, Birrer MJ, Cho KR, Ellenson LH, Gorstein F, Seidman JD, Current challenges and opportunities for research on borderline ovarian tumors, Hum Pathol, 2004, 35(8):961-970.
11. Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih IeM, Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation, Am J Surg Pathol, 2005, 29(2):218-224.
12. Morita K, Ono Y, Fukui H, Tomita S, Ueda Y, Terano A, Fujimori T, Incidence of P53 and K-ras alterations in ovarian mucinous and serous tumors, Pathol Int, 2001, 50(3):219-223.
13. Lee JH, Kang YS, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Kavanagh JJ, Wharton JT, p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor, Cancer Genet Cytogenet, 1995, 85(1):43-50.
14. Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS, Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors, Am J Surg Pathol, 1999, 23(3): 323-328.
15. Kupryjanczyk J, Bell DA, Dimeo D, Beauchamp R, Thor AD, Yandell DW, p53 gene analysis of ovarian borderline tumors and stage I carcinomas, Hum Pathol, 1995, 26(4):387-392.
16. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors, Gynecol Oncol, 1994, 52(2):232-236.
17. O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG, An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms, Am J Surg Pathol, 2005, 29(8):1034-1041.
18. Kupryjańczyk J, Bell DA, Yandell DW, Scully RE, Thor AD, P53 expression in ovarian borderline tumors and stage I carcinomas, Am J Clin Pathol, 1994, 102(5):671-676.
19. Klemi PJ, Takahashi S, Joensuu H, Kiilholma P, Narimatsu E, Mori M, Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors, Int J Gynecol Pathol, 1994, 13(3): 228-233.
20. Röhlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Löning T, p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity, J Cancer Res Clin Oncol, 1997, 123(9):496-501.
21. Henriksen R, Strang P, Wilander E, Bäckström T, Tribukait B, Oberg K, p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry, Gynecol Oncol, 1994, 53(3): 301-306.
22. Henriksen R, Strang P, Backstrom T, Wilander E, Tribukait B, Oberg K, Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers, Anticancer Res, 1994, 14(2B):603-608.
23. Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ, Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors, Hum Pathol, 2000, 31(6):698-704.
24. Garzetti GG, Ciavattini A, Goteri G, De Nictolis M, Stramazzotti D, Lucarini G, Biagini G, Ki67 antigen immuno-staining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance, Gynecol Oncol, 1995, 56(2):169-174.
25. Halperin R, Zehavi S, Dar P, Habler L, Hadas E, Bukovsky I, Schneider D, Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas, Eur J Gynaecol Oncol, 2001, 22(4):292-296.
26. Zheng W, Luo F, Lu JJ, Baltayan A, Press MF, Zhang ZF, Pike MC, Reduction of BRCA1 expression in sporadic ovarian cancer, Gynecol Oncol, 2000, 76(3):294-300.
27. Shih IeM, Kurman RJ, Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis, Am J Pathol, 2004, 164(5):1511-1518.
28. Choudhury M, Goyal S, Pujani M, A cytohistological study of Ki-67 expression in ovarian tumors, Indian J Pathol Microbiol, 2011, 54(1):21-24.